ChiCTR2300070780 版本V1.0 版本创建时间2023/04/23 15:42:42 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300070780 

最近更新日期:

Date of Last Refreshed on:

2023-04-23 15:42:39 

注册时间:

Date of Registration:

2023-04-23 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

软性亲水接触镜用于成年散光患者视力矫正的真实世界研究

Public title:

A real-world study on the use of soft hydrophilic contact lenses for visual correction in adult astigmatism patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

软性亲水接触镜用于成年散光患者视力矫正的真实世界研究

Scientific title:

A real-world study on the use of soft hydrophilic contact lenses for visual correction in adult astigmatism patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

叶璐 

研究负责人:

叶璐 

Applicant:

Ye Lu 

Study leader:

Ye Lu 

申请注册联系人电话:

Applicant telephone:

+86 029 61220086

研究负责人电话:

Study leader's
telephone:

+86 029 61220086

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

dryelu@126.com

研究负责人电子邮件:

Study leader's E-mail:

dryelu@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

陕西省西安市新城区解放路21号

研究负责人通讯地址:

陕西省西安市新城区解放路21号

Applicant address:

No. 21 Jiefang Road, Xincheng District, Xi'an City, Shaanxi Province

Study leader's address:

No. 21 Jiefang Road, Xincheng District, Xi'an City, Shaanxi Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

西安市人民医院(西安市第四医院)陕西省眼科医院

Applicant's institution:

Biomedical ethics review committee of Xi'an People's Hospital (Xi'an Fourth Hospital)

研究负责人所在单位:

西安市人民医院(西安市第四医院)陕西省眼科医院

Affiliation of the Leader:

Biomedical ethics review committee of Xi'an People's Hospital (Xi'an Fourth Hospital)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

20220146

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

西安市人民医院(西安市第四医院)医学伦理委员会

Name of the ethic committee:

Biomedical ethics review committee of Xi'an People's Hospital (Xi'an Fourth Hospital)

伦理委员会批准日期:

Date of approved by ethic committee:

2022-11-22 00:00:00

伦理委员会联系人:

冯燕

Contact Name of the ethic committee:

Feng Yan

伦理委员会联系地址:

陕西省西安市解放路21号

Contact Address of the ethic committee:

No. 21, Jiefang Road, Xi'an, Shaanxi Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 029 89623908

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

陕西省西安市人民医院(西安市第四医院)陕西省眼科医院

Primary sponsor:

Shaanxi Eye Hospital, Xi 'an People's Hospital (Xi 'an Fourth Hospital)

研究实施负责(组长)单位地址:

陕西省西安市解放路21号

Primary sponsor's address:

No. 21, Jiefang Road, Xi'an, Shaanxi Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

陕西省

市(区县):

西安

Country:

China

Province:

ShanXi Province

City:

Xian

单位(医院):

西安市人民医院(西安市第四医院)

具体地址:

陕西省西安市解放路21号

Institution
hospital:

Shaanxi Eye Hospital, Xi 'an People's Hospital (Xi 'an Fourth Hospital)

Address:

No. 21, Jiefang Road, Xi'an, Shaanxi Province

经费或物资来源:

陕西省重点研发计划

Source(s) of funding:

Key R&D Plan of Shaanxi Province

研究疾病:

屈光不正  

Target disease:

ametropia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

单臂 

Study design:

Single arm 

研究目的:

通过3个月的随访,评价吉恩吉隐形眼镜(G&G Contact Lens)生产的软性亲水接触镜(型号:G&G POP·CT)用于成年近视及散光患者视力矫正的安全性、有效性,以及美容效果。  

Objectives of Study:

Through a 3-month follow-up, evaluate the safety, effectiveness, and cosmetic effects of the soft hydrophilic contact lenses (model: G&G POP · CT) produced by G&G Contact Lens for correcting vision in adult myopia and astigmatism patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1) 年满18周岁的患者;
2) 双眼球镜度数均在0.00D~-10.00D之间(包含0.00D和-10.00D),散光度数均在-0.50D~-3.75D之间(包含-0.50D和-3.75D),散光轴向均在0~180°的患者;
3) 双眼框架镜最佳矫正视力(远用)均能达到0.8的患者;
4) 经医生判断眼底正常者;
5) 能够完成至少3个月随访的患者;
6) 对接触镜或接触镜护理产品任何成分无过敏者;
7) 非妊娠期、哺乳期或近期无怀孕计划者;
8) 无禁忌症患者;
9) 能够理解随访研究目的,自愿参加并由受试者本人签署知情同意书者。

Inclusion criteria

1) Patients over the age of 18;
2) Patients with binocular spherical mirror powers ranging from 0.00D to 10.00D (including 0.00D and -10.00D), astigmatism powers ranging from -0.50D to -3.75D (including -0.50D and -3.75D), and astigmatism axes ranging from 0 to 180 °;
3) Patients with optimal corrected visual acuity (for remote use) of both binocular frames reaching 0.8;
4) Those with normal fundus as judged by a doctor;
5) Patients who can complete at least 3 months of follow-up;
6) Those who are not allergic to any component of contact lenses or contact lens care products;
7) Those who are not pregnant, breastfeeding, or have no recent pregnancy plans;
8) Patients without contraindications;
9) Those who can understand the purpose of the follow-up study, voluntarily participate and have the informed consent form signed by the subjects themselves.

排除标准:

1) 患有可能影响眼部的全身性疾病,经研究者判定不能配戴软性接触镜者,如红斑狼疮、硬皮病、不能控制的糖尿病等;
2) 患有眼部疾病者,经研究者判定不能配戴软性接触镜者,如眼部急性或慢性炎症、青光眼、角膜知觉异常、角膜上皮缺损、角膜内皮细胞减少、严重的干眼症等;
3) 有接触镜过敏史或接触镜护理产品过敏史者;
4) 有眼外伤史或眼内手术史者;
5) 任一眼眼压>21mmHg的患者;
6) 裂隙灯检查异常,但不排除异常≤1级者;
7) BUT≤5s的患者;
8) 个人卫生条件不具备配戴软镜所必需的卫生条件者,如生活或工作环境中弥散粉尘、药品、气雾剂(如发胶、挥发性化学物)和灰尘等;
9) 正在使用或随访研究期间需要使用可能会导致干眼或影响视力等药物(如青霉素、链霉素、氯霉素、磺胺类、异烟肼、乙胺丁醇等)的患者;
10) 30天内配戴过硬性接触镜者;
11) 筛选前7天内参加过软性接触镜试验,30天内参加过其他医疗器械试验,3个月内参加过药物试验者;
12) 孕妇、哺乳期或近期计划怀孕者;
13) 不能按医嘱配戴接触镜并按时随访者;
14) 研究者判断不适合入选的其他情况。

Exclusion criteria:

1) Those who suffer from systemic diseases that may affect the eyes and cannot wear soft contact lenses as determined by the researcher, such as lupus erythematosus, scleroderma, uncontrollable diabetes, etc;
2) People with eye diseases who cannot wear soft contact lenses as determined by the researcher, such as acute or chronic eye inflammation, glaucoma, abnormal corneal perception, corneal epithelial defect, corneal endothelial cell reduction, severe dry eye, etc;
3) Individuals with a history of contact lens allergies or allergies to contact lens care products;
4) Individuals with a history of eye injury or intraocular surgery;
5) Patients with any intraocular pressure greater than 21mmHg;
6) Slit lamp inspection is abnormal, but it is not ruled out that the abnormality is ≤ level 1;
7) Patients with BUT ≤ 5s;
8) Individuals who do not have the necessary hygiene conditions for wearing soft glasses, such as dispersed dust, drugs, aerosols (such as hair gel, volatile chemicals), and dust in their living or working environment;
9) Patients who are using or need to use drugs that may cause dry eyes or affect vision (such as penicillin, streptomycin, chloramphenicol, sulfonamides, isoniazid, ethambutol, etc.) during follow-up study;
10) Those who have worn rigid contact lenses within 30 days;
11) Individuals who have participated in soft contact lens testing within 7 days before screening, other medical device testing within 30 days, and drug testing within 3 months;
12) Pregnant women, breastfeeding or recently planned pregnancies;
13) Those who are unable to wear contact lenses according to medical advice and follow up on time;
14) Other situations that the researcher determines are not suitable for inclusion.

研究实施时间:

Study execute time:

From 2022-11-30 00:00:00 To 2023-04-23 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-12-01 00:00:00 To 2023-01-31 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

700

Group:

Experimental group

Sample size:

干预措施:

配戴隐形眼镜

干预措施代码:

Intervention:

Wear contact lenses

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

陕西省 

市(区县):

 

Country:

China

Province:

ShaanXi Province

City:

单位(医院):

西安市人民医院(西安市第四医院) 

单位级别:

三级甲等 

Institution
hospital:

Xi 'an People's Hospital (Xi 'an Fourth Hospital)

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

戴镜视力

指标类型:

主要指标

Outcome:

Glassed vision

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

美容效果

指标类型:

主要指标

Outcome:

Beauty effects

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

接触镜矫正视力

指标类型:

次要指标

Outcome:

Contact lens correction of vision

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

裸眼视力

指标类型:

附加指标

Outcome:

Naked vision

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

屈光度

指标类型:

附加指标

Outcome:

Diopter

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

裂隙灯检查

指标类型:

副作用指标

Outcome:

Slit lamp examination

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 40 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不涉及

Randomization Procedure (please state who generates the random number sequence and by what method):

Not involved

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

暂未确定是否共享原始数据,网络平台临床试验公共管理平台 (http://www.medresman.org.cn/login.aspx)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

It has not been determined whether raw data will be shared. Clinical Trial Management Public Platform(http://www.medresman.org.cn/login.aspx)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用病历记录表的方式采集数据。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data were collected in the form of CRF.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-04-23 15:42:39